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Abstract
Background: Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique that has shown
promise for the ablation of lesions in proximity to vital structures such as blood vessels and bile ducts. The primary
aim of the COLDFIRE-2 trial is to investigate the efficacy of IRE for unresectable, centrally located colorectal liver
metastases (CRLM). Secondary outcomes are safety, technical success, and the accuracy of contrast-enhanced
(ce)CT and 18F-FDG PET-CT in the detection of local tumor progression (LTP).
Methods/design: In this single-arm, multicenter phase II clinical trial, twenty-nine patients with 18F-FDG PET-avid
CRLM ≤ 3,5 cm will be prospectively included to undergo IRE of the respective lesion. All lesions must be
unresectable and unsuitable for thermal ablation due to vicinity of vital structures. Technical success is based on
ceMRI one day post-IRE. All complications related to the IRE procedure are registered. Follow-up consists of 18F-FDG
PET-CT and 4-phase liver CT at 3-monthly intervals during the first year of follow-up. Treatment efficacy is defined
as the percentage of tumors successfully eradicated 12 months after the initial IRE procedure based on clinical
follow-up using both imaging modalities, tumor marker and (if available) histopathology. To determine the
accuracy of 18F-FDG PET-CT and ceCT, both imaging modalities will be individually scored by two reviewers
that are blinded for the final oncologic outcome.
Discussion: To date, patients with a central CRLM unsuitable for resection or thermal ablation have no curative
treatment option and are given palliative chemotherapy. For these patients, IRE may prove a life-saving treatment
option. The results of the proposed trial may represent an important step towards the implementation of IRE for
central liver tumors in the clinical setting.
Trial registration: Trial registration number: NCT02082782.
Keywords: Irreversible electroporation (IRE), Liver neoplasms/secondary, Local, FDG-PET, PET-CT, Tumor ablation,
Neoplasm recurrence, Colorectal liver metastases
Background
Colorectal cancer causes each 10th death due to cancer
in Western countries. About 33 % of all patients with
colon cancer have liver-only metastatic disease [1]. For
these patients, surgical resection is the gold standard,
with 5-year survival rates up to 60 % [2, 3]. However,
despite improvements of surgical techniques and current
neoadjuvant chemotherapies, only 5–20 % of patients
with colorectal liver metastases (CRLM) can benefit
from surgery due to number, localization, or distribution
of tumors [4].
In light of the limitations of surgical resection for
many hepatic tumors, a number of ablative technologies
for liver-directed therapy have developed during the last
20 years [5]. Of these techniques, thermal ablation using
radiofrequency ablation (RFA) and microwave ablation
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(MWA) are most frequently used. A recent review
showed a local recurrence rate of 2.8–29.7 % of RF-
ablated liver lesions at 12–49 months follow-up, and
2.7–12.5 % of MW-ablated lesions at 5–19 months
follow-up, with a 5-year survival rate around 30 % for
both techniques [6]. Although thermal ablation has
dramatically improved survival rates for patients with
CRLM, factors like size and location limit its use and
effectiveness. Efficacy of RFA rapidly decreases for
lesions > 3 cm [7]. Also, the rate of complete tumor
necrosis falls below 50 % when vessels larger than 3 mm
abut the tumor as a consequence of the heat-sink effect
[8]. Ablation of lesions close to vital structures like
major bile ducts and vessels is associated with a substan-
tial risk of complications due to thermal damage.
Irreversible electroporation (IRE) is a novel ablation
modality that may overcome some of the limitations of
current thermal ablation therapies. It is based on a
pulsating current created between multiple needle elec-
trodes placed around the target lesion which alters the
existing cellular transmembrane potential. If the dur-
ation of the applied electrical pulses is below the char-
ging time of the outer cell membrane, an interaction of
the electric field with subcellular structures occurs [9].
This interaction results in permanent permeabilization
of the cell membrane, which disrupts cellular homeosta-
sis and ultimately leads to cell death. The irreversibly
damaged cells are removed by the immune system [10].
Two main factors stimulate research into IRE as an
ablation modality. Since the mechanism of cell death is
predominantly nonthermal, connective tissue structure
is preserved, so there is no damage to associated blood
vessels and bile ducts [11–13]. For the same reason,
treatment efficacy is not impeded by heat-sink [14]. This
allows for treatment of liver tumors deemed unresect-
able or ineligible for other focal ablation techniques due
to localization near these structures [15].
The capability of IRE to destroy CRLM in humans was
recently demonstrated in the COLDFIRE-1 ablate-and-
resect trial [16]. In this trial resectable CRLM were
treated with IRE, followed by resection one hour later.
The investigators demonstrated cell death of the ablated
tumors within one hour after IRE, with intact larger vas-
cular and ductal structures within the ablation zone. The
first studies investigating hepatic IRE on clinical indica-
tion also yield promising results. A systematic review
found an overall complication rate of 16 % for hepatic
IRE, similar to RFA [17]. However, the tumors treated
with IRE were all located near thermally sensitive
structures, as opposed to the thermally ablated lesions.
Complete tumor eradication was achieved in 67–100 %,
and this percentage was even higher for tumors < 3 cm
[17]. However, since most studies are retrospective
with short-term follow-up using heterogeneous study
populations and design, the value of the current
evidence remains limited. Also, the optimal imaging
modality for follow-up after IRE needs to be analyzed.
The primary aim of the COLDFIRE-2 trial is to inves-
tigate the efficacy of IRE for CRLM that are unsuitable
for resection and thermal ablation due to the vicinity of
vulnerable structures such as bile ducts, vessels and
bowel. Other outcomes are safety of IRE, and the accur-
acy of contrast-enhanced computed tomography (ceCT)
and 18F-fluorodeoxyglucose (FDG) positron emission




The COLDFIRE-2 trial is a phase II, multicenter, prospect-
ive single-arm trial that is organized by the VU University
Medical Center in Amsterdam, the Netherlands. Patients
will be recruited at three academic hospitals in the
Netherlands (VU University Medical Center, Amsterdam;
Academic Medical Center, Amsterdam; Leiden University
Medical Center, Leiden). The study protocol has been
approved by the Medical Ethical Review Board of the VU
University Medical Center. The trial is investigator-
sponsored, independent of industry and is registered at
clinicaltrials.gov under number NCT02082782. The trial
will be conducted in accordance with the Declaration of
Helsinki. The inclusion and exclusion criteria for the
COLDFIRE-2 trial are summarized in Table 1.
Eligibility criteria
All patients are treated with curative intent and must
have received previous chemotherapy for CRLM at some
stage in their disease. Prior to inclusion, all patients will
be discussed in a multidisciplinary liver tumor board
consisting of a hepatogastroenterologist, hepatobiliary sur-
geon, medical oncologist, radiation oncologist, abdominal
and interventional radiologist. Decision on treatment will
Table 1 In- and exclusion criteria
Inclusion criteria Exclusion criteria




Radiologic proof of colorectal liver
metastasis, unsuitable for resection
and thermal ablation due to vicinity
to vascular or ductal structures
Congestive heart failure,
NYHA Class≥ 3
18F FDG-PET avidity of target lesion
and visible on ceCT
Active coronary artery
disease
Lesion size≤ 3.5 cm History of epilepsy




ASA-classification 0–3 Chemotherapy <6 weeks
prior to treatment
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be at their discretion. Patients who present with more
than one metastasis can only be included if treatment with
curative intent is still realistic and if all lesions can be
treated during the same session or within six weeks after
the IRE procedure. Thermal ablation or resection of con-
comitant lesions during the same session is therefore
allowed and limited extrahepatic disease, defined as ≤5
nodules in the lung and/or one other metastatic site which
is amenable to future definitive treatment, is not contra-
indicated [18]. All participants from all participating
centers will provide written informed consent.
IRE procedure
Depending on concurrent treatment of other lesions
(surgical resection or thermal ablation), patients will
either be treated during an open procedure using intra-
operative ultrasound (IOUS), or percutaneously using CT.
Patients undergoing laparotomy will receive a thoracic
epidural before surgery. For percutaneous procedures, to
allow repeated and real-time visualization of both the
tumor and the adjacent vessels, a catheter is placed within
the common hepatic artery approaching from the right
femoral artery. Technical details of this procedure have
been previously described by Van Tilborg et al. [19]. All
procedures will be performed under general anesthesia,
induced with propofol, sufentanil, and rocuronium and
maintained with propofol and remifentanil. First, the exact
three-dimensional measurements of the target lesion are
defined using IOUS or aortic catheter based CT. The
planned electrode configuration must result in an
expected geometry of the ablation zone that fully covers
the tumor and a tumor-free margin of at least 5 mm in all
directions [20]. Depending on the size, 2–6 needle elec-
trodes (NanoKnife, AngioDynamics, Latham, NY) with an
active working length of 20 mm are positioned in the
outer border or just adjacent to the tumor under IOUS or
CT guidance, aiming at an inter-electrode distance of
20 mm (±2 mm). All needles are placed parallel to each
other to promote homogeneous energy delivery. After
confirmation of correct distances with IOUS or with
unenhanced CT using multiplanar reformatting, ten test-
pulses of 1500 V/cm and 90 μs are delivered via each elec-
trode pair, after which the delivered current is verified.
The target current lies between 20–50A and voltage
settings are manually adjusted in case of over- or under-
current. Subsequently, three cycles of 30 pulses are
administered to reach a total of 100 pulses per electrode
pair. If more than 6 electrodes are needed for larger
tumors, electrodes are repositioned to perform overlap-
ping ablations. Similarly, for tumors with a depth larger
than 20 mm, after ablation of the deepest part of the
tumor a 1.5 cm pullback of the electrodes is performed to
treat the superficial part. Immediately after IRE, a control
aortic catheter CT or IOUS is made to evaluate technical
success and to exclude early complications. The next day,
ceMRI is performed to verify patency of vascular and
ductal structures, as well as technical success. In case of
incomplete ablation on ceMRI, the suspected residual
tumor will be retreated in the following weeks. A flow
diagram of the trial is shown in Fig. 1.
Imaging
Four-phase liver CT and 18F-FDG PET-CT will be per-
formed before IRE, and 3, 6, 9 and 12 months after IRE.
Imaging is conducted according to EANM guidelines with
the same 18F-FDG PET-CT in each participating center
(Philips Gemini TF PET-CT system, Philips Medical
Systems, Cleveland, Ohio, USA) [21]. Whole body 18F-
FDG PET (skull base to mid-thigh) starts 60 min after
FDG injection, followed by a low-dose CT for attenuation
correction and anatomical co-localization of 18F-FDG
PET-findings. Next, a diagnostic 4-phase CT of the liver is
performed. Scanning parameters are shown in Table 2.
Treatment response is primarily based on a per-lesion
analysis. The standard of reference is defined by a combin-
ation of 4-phase liver CT and 18F-FDG PET-CT, and, if
available, histologically proven malignancy. Pathologically
elevated carcinoembryonic antigen (CEA) is used when
appropriate (e.g. if no other metastases are present).
Treatment response on 4-phase liver CT is assessed
using the Response Evaluation Criteria In Solid
Tumors (RECIST) [22]. The Positron Emission tom-
ography Response Criteria In Solid Tumors (PER-
CIST) criteria are used for 18F-FDG PET-CT [23]. On
4-phase liver CT, LTP is defined as a growing (>20 %;
longest diameter; axial plane) hypodense lesion within
1 cm of the ablation zone. On 18F-FDG PET-CT,
focally increased FDG uptake within 1 cm of the
ablation region is considered an LTP [24]. If LTP is
suspected on both modalities during follow-up, the
patient will be evaluated for re-treatment in our
multidisciplinary liver tumor board. To establish the
value of PET-CT and ceCT for the prediction of LTP
the suspected area will be biopsied in the same
session prior to re-treatment, although the suspicious
lesion will be re-ablated regardless. In case of discrep-
ancy between the 4-phase liver CT and 18F-FDG
PET-CT findings, a liver MRI will be performed as
problem solver. If MRI is also inconclusive, multidis-
ciplinary deliberation will decide upon either repeat
imaging 3 months later, or biopsy of the suspected
recurrence. If chemotherapy is indicated during follow-
up (e.g. due to new metastatic disease), the patient will
remain in follow-up. The trial will end twelve months after
the last IRE procedure. If no LTP or new metastatic
disease has been diagnosed at this moment, regular
follow-up will be resumed consisting of 6-monthly
18F-FDG PET-CT and 4-phase liver CT.
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Data collection and handling
The study coordinators (HS and LV) will collect the
data. All data will be handled confidentially and an-
onymously. A subject identification code is used to link
the data to the subject. The study coordinators safeguard
the key to the identification code. The handling of
personal data will comply with the Dutch Personal Data
Protection Act.
To investigate the accuracy of 18F-FDG PET-CT and
4-phase liver CT in the diagnosis of LTP after IRE,
twelve months after the last IRE treatment blinded data
sets from all centers will be reviewed separately and
independently by two designated radiologists (BvdM
and JvdB) and two nuclear medicine physicians (OH
and EC) in a consensus reading. Each lesion will be
scored on a separate form on a one to five scale
(Table 3) [25]. The reviewers will be blinded to the
results of the other imaging modality and to the final
oncologic outcome as determined by the standard of
reference.
Primary and secondary objectives
The primary endpoint of the COLDFIRE-2 trial is efficacy
of IRE for CRLM. Secondary endpoints are progression-
free survival (PFS) and overall survival (OS). Other
secondary endpoints are safety, technical success, and the
accuracy of 18F-FDG PET-CT and 4-phase liver CT in the
detection of LTP after IRE.
Primary efficacy rate is defined as the percentage of
target tumors successfully eradicated 12 months after
the initial IRE procedure, according to the RECIST and
PERCIST criteria. Secondary efficacy rate is defined as
the percentage of tumors successfully eradicated
12 months after the initial IRE procedure, including
tumors that have undergone successful repeat ablation
following identification of LTP [26].
Progression-free survival is defined as the time from
the first IRE procedure to the time of radiologic disease
progression or death of disease. Overall survival is
defined as the time from the IRE procedure until death
of disease [27]. Both PFS and OS will be determined
Fig. 1 Flow diagram of study procedure
Table 2 Scanning parameters of 18 F-FDG PET-CT and 4-phase liver CT
Delay (sec) Contrast Matrix Pixel size (mm2) Slice thickness (mm) Current (mAs/slice) Energy (keV)
Whole body PET 18F FDG (ref) 144 × 144 4 × 4 5
Low-dose CT - 512 × 512 1.17 × 1.17 5 30–50 100
4-phase liver CT 100 ml 512 × 512 0.68 × 0.68 4–5
- Precontrast Xeneti × 300 220 AEC 120
- Arterial 12 450 AEC 80
- Venous 50 220 AEC 120
- Hepatic 220 175 AEC 120
AEC; Automated exposure control
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using the Metabolic Imaging And Marker Integration
(MIAMI) criteria as proposed by Hosein and colleagues,
which integrates anatomic response parameters (4-phase
liver CT) with two functional parameters: PET activity
and CEA levels [28]. For safety analysis, all major
adverse events and all adverse events occurring during
or within 12 months after IRE treatment will be re-
corded according to the Common Terminology Criteria
of Adverse Events (CTCAE) v4.0 [29]. Pain assessment
using the visual analogue scale (VAS) and patient anal-
gesic consumption will be recorded. Patency of vessels
and bile ducts on follow-up cross-sectional imaging will
be analyzed to identify late complications. Technical
success is defined as (1) the ability to successfully deliver
all planned pulses according to protocol and (2) complete
lesion coverage on post-procedure ceCT or IOUS, and
24–48 h post-procedure MRI [26].
Sample size calculation and statistical considerations
Based on the current literature our hypothesis is that 10 %
of the treated tumors will recur after the initial treatment
(primary technique efficacy 90 %), which implies a local
recurrence rate of 0.1 [5, 30]. Choosing a target width of
0.25 with p ≤ 0.05, we used the confidence interval
formula “Exact” for two-sided confidence intervals for one
proportion (Clopper-Pearson) [31, 32]. With this formula,
actual width is 0.249, with a 95 % confidence interval of
0.020–0.269. This calculation results in a sample size of
29 patients. Considering a 5 % loss to follow-up, the total
number of patients needed is 31.
All clinicopathological and procedural variables will be
described and analyzed. Continuous variables will be
summarized with standard descriptive statistics includ-
ing means, standard deviations, medians and ranges.
Categorical variables will be summarized with frequen-
cies. P-values ≤ 0.05 will be considered statistically
significant. Univariate survival analysis will be performed
using the Kaplan-Meier method. Differences in local
recurrence rate between subgroups like tumor size and
adjuvant chemotherapy will be analyzed descriptively
since the expected number of recurrences is too small
for statistical analysis.
The accuracy of 18F-FDG PET-CT and 4-phase liver
CT in diagnosing local recurrences will be investigated
by comparison to the reference standard. Interobserver-
variability will be determined using Cohen’s Kappa.
Sensitivity and specificity of both techniques will be cal-
culated with their respective 95 % confidence intervals.
McNemar’s test is used to assess a statistically significant
difference between both imaging modalities.
Discussion
IRE for colorectal liver metastases
New cancer treatments are typically best defined from
phase III randomized trials comparing the investigated
therapy with the current standard. However, in the field of
local tumor ablation, this has proven a difficult challenge.
Since its introduction decades ago, the number of
randomized trials remains limited. An attempt to organize
a trial comparing RFA to surgical resection has failed
(French FFCD 2002–02) and it is unlikely that another
trial can be organized in the near future [33]. The current
literature on the clinical application of IRE is scarce with
no randomized controlled trials. However, because the
indication for IRE lies with tumors in which no other
suitable local therapy is available, a randomized trial com-
paring IRE to e.g. surgical resection or thermal ablation is
not unrealistic at this point in time.
Results of single-arm studies on hepatic IRE report a
high variation in efficacy, with local recurrence rates be-
tween 67–100 % [17]. Similar to RFA, efficacy is higher
for tumors ≤ 3 cm. However, since IRE is only used as a
‘last resort’ curative treatment option in patients that
would otherwise receive palliative chemotherapy, these
early efficacy rates are promising and encourage larger
prospective studies.
Feasibility
Intraprocedural monitoring and control of ablation
play a critical role in the success of tumor ablation
[34]. The feasibility of real-time monitoring with US
during hepatic IRE has been demonstrated in both
animal and human studies. The ablation zone imme-
diately appears as a hypoechoic area with well-defined
Table 3 Study form for reviewers’ results (per lesion)
Study number Reviewer number
Score Definition Explanation
1 Normal Confident that no tumor recurrence is present in the ablation zone
2 Probably benign The appearance of the ablated lesion is compatible with post-ablational inflammation or rim-like characteristics
3 Equivocal There is doubt whether the imaging features indicate local tumor progression or inflammation
4 Probably malignant Confident about local progression in the ablation zone
5 Impaired quality Quality of the images precludes adequate diagnosis
Comments:
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margins [16, 35, 36]. Immediate postprocedure ceCT also
shows a well-defined hypodense area on the portal venous
phase with variable periablational hyperenhancement
[37, 38]. The size and shape of the IRE ablation zone
on both US and CT has proven to correlate reliably with
the pathologically defined zone of cell death [36, 37].
These imaging modalities could therefore be used to en-
sure that the realm of ablation encompasses the originally
targeted volume with a sufficient margin [15], which is a
focus of the presented trial.
Imaging follow-up
The main concern following tumor ablation is the risk
of developing LTP. Early diagnosis of LTP is imperative
because repeated treatment can still effectuate complete
tumor clearance, especially for smaller recurrences.
CeCT is the current mainstay of staging and follow-up
[39]. One shortcoming of ceCT in the monitoring of
post-ablative lesions for recurrent disease is the presence
of post-ablation effects. Because reactive tissue and
viable tumor can both present as hypodensity around
the ablated lesion, their distinction can be difficult [24].
Due to the visualization of increased glucose metabolism
in tumor cells, 18F-FDG PET has proven a very sensitive
and accurate tool for the diagnosis of tumor manifesta-
tions in patients with colorectal carcinoma [39]. Using
18F-FDG PET-CT, 18F-FDG PET images are combined
with CT in a single session. Anatomical and morpho-
logical information from CT is used to increase the
precision of localization, extent, and characterization of
lesions detected by 18F-FDG PET [21]. Several studies
have shown the superiority of 18F-FDG PET-CT over
morphologic imaging alone in the follow-up after
ablation of CRLM: sensitivity and specificity for the
detection of LTP are 92 % 100 % for 18F-FDG PET-
CT compared to 83 % and 100 % for ceCT [24].
However, the diagnostic accuracy of 18F-FDG PET
and 18F-FDG PET-CT is strongly affected by che-
motherapy, so for patients receiving chemotherapy
during follow-up after IRE ceCT may prove the most
reliable imaging modality.
After IRE, immediate ceCT shows a hypodense ablation
zone that does not enhance post-contrast. A transient per-
ipheral rim of contrast enhancement can be present,
representing hyperemia [15]. In the months after ablation,
the ablation zone slowly decreases in size and should not
show uptake of contrast. PET scans show a dynamic
response to the IRE ablation. Three days following IRE, an
18F-FDG-avid peripheral zone surrounding the ablated
region appears. This initial increase in uptake at the
periphery of the IRE region may be explained by an in-
flammatory response, increasing metabolic activity at the
targeted region as the cellular debris is removed from the
ablation site [15]. In our experience the inflammatory
response can persist for several months, which renders
evaluation of the ablation zone with 18F-FDG PET
difficult. On the contrary, ablated lesions that show
focal rather than rim-like uptake in the periphery are
considered suspect for local recurrence. Because
much is still unknown about the imaging characteris-
tics of liver lesions treated with IRE, standardized
follow-up regimens are lacking. The COLDFIRE-2
trial focuses on the typical imaging characteristics of
electroporated CRLM over time. The gold standard for
LTP is histologic confirmation. With biopsies taken from
all suspicious lesions prior to re-treatment, the trial also
assesses the accuracy of the pre-defined definition of LTP
on PET-CT and ceCT.
A potentially curative treatment option for a group of
patients that is currently offered chemotherapy with pal-
liative intent is of major importance. IRE may prove a
safe and valuable fortification in the armory of interven-
tional oncologists treating patients with liver tumors.
The aim of the COLDFIRE-2 trial is to contribute to the
available evidence on IRE with respect to safety, efficacy,
imaging characteristics and follow-up guidelines. The
results of the proposed trial may represent an important
step towards the implementation of IRE for central liver
tumors in the clinical setting.
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